Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-1,4-galactosyltransferase 4 (B4GALT4) is an enzyme encoded by the B4GALT4 gene, belonging to the glycosyltransferase family 7 (GT7), and is categorized as a type II membrane-bound glycoprotein localized mainly to the Golgi apparatus[1][2][3]. It catalyzes the transfer of galactose from UDP-galactose to terminal N-acetylglucosamine, glucose, or xylose residues in a beta-1,4 linkage, playing a specific role in the biosynthesis of glycoproteins, glycolipids (notably neolacto-series glycosphingolipids), and keratan sulfate[1][2][3]. The enzyme is crucial for forming N- and O-linked keratan sulfate proteoglycans and participates in the construction and elongation of mono- and disulfated disaccharide units in keratan sulfate, working cooperatively with other glycosyltransferases and sulfotransferases[2]. Loss or dysfunction of B4GALT4 leads to profound reduction in keratan sulfate synthesis and is associated with congenital disorders of glycosylation and spondylodysplastic Ehlers-Danlos syndrome types[1][2]. B4GALT4 is additionally characterized by essential N-glycosylation sites that determine its Golgi localization, stability, and enzymatic activity[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-1,4-galactosyltransferase 4 (B4GALT4).